These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 6339196)

  • 41. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
    Opie LH
    Q J Med; 1984; 53(209):1-16. PubMed ID: 6324268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.
    Soward AL; Vanhaleweyk GL; Serruys PW
    Drugs; 1986 Jul; 32(1):66-101. PubMed ID: 2874975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration.
    Yeung PK; Mosher SJ; Pollak PT
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):69-74. PubMed ID: 1936064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.
    Choi JS; Burm JP
    Arch Pharm Res; 2005 Apr; 28(4):483-7. PubMed ID: 15918524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats.
    Choi HJ; Choi JS
    Arch Pharm Res; 2005 Aug; 28(8):970-6. PubMed ID: 16178425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
    Böttiger Y; Säwe J; Brattström C; Tollemar J; Burke JT; Häss G; Zimmerman JJ
    Clin Pharmacol Ther; 2001 Jan; 69(1):32-40. PubMed ID: 11180036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.
    Anderson P; BondessoN U; Sylvén C
    Eur J Clin Pharmacol; 1982; 23(1):49-57. PubMed ID: 7128672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.
    Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A
    Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of calcium antagonists.
    Reid JL; Meredith PA; Donnelly R; Elliott HL
    J Cardiovasc Pharmacol; 1988; 12 Suppl 7():S22-6. PubMed ID: 2467122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
    Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
    Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
    Kiyomoto A; Sasaki Y; Odawara A; Morita T
    Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of calcium antagonists on sympathetic nerve activity.
    Zsotér TT; Wolchinsky C
    Can J Cardiol; 1986; 2(4):256-60. PubMed ID: 3768782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
    Hermann DJ; Krol TF; Dukes GE; Hussey EK; Danis M; Han YH; Powell JR; Hak LJ
    J Clin Pharmacol; 1992 Feb; 32(2):176-83. PubMed ID: 1613128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Side effects of calcium channel blockers.
    Russell RP
    Hypertension; 1988 Mar; 11(3 Pt 2):II42-4. PubMed ID: 3280492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Drug interactions with calcium inhibitors in man].
    Cheymol G; Engel F
    Therapie; 1989; 44(3):189-96. PubMed ID: 2571195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation.
    Shenasa M; Kus T; Fromer M; LeBlanc RA; Dubuc M; Nadeau R
    Am J Cardiol; 1988 Sep; 62(7):403-7. PubMed ID: 3414517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Differential therapy with calcium antagonists. Hemodynamic studies using nifedipine, verapamil and diltiazem].
    Lehmann HU; Hochrein H
    Dtsch Med Wochenschr; 1985 Apr; 110(17):674-80. PubMed ID: 3987531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physiological disposition of verapamil in man.
    Schomerus M; Spiegelhalder B; Stieren B; Eichelbaum M
    Cardiovasc Res; 1976 Sep; 10(5):605-12. PubMed ID: 971476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.